With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics, Inc.'s ...

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment ...

Candel priced its $80 million underwritten public offering of shares and pre-funded warrants. The company plans to use the funds from the public offering to advance its product candidates. Get ahead ...

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday potentially driven by continued momentum following the company’s announcement of positive phase 3 trial results for its ...

Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Fraiser Kansteiner, and we will ...

Shares of Candel Therapeutics Inc. CADL climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment. Pancreatic cancer patients who received the ...

Candel Therapeutics appointed Charles Schoch as chief financial officer after he served on an interim basis from January 2024. The biopharmaceutical company said Schoch joined Candel in November 2021 ...

Amello says working in healthcare gives him the opportunity to affect people's lives in a profound way. As a young man, Jason Amello wanted to be a musician, because he likes how music can reach and ...

A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will be archived for ...